Segmental Reporting

9 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure

18.       Segmental reporting

Historically the Company had three business units and three reportable segments: Specialty Pharmaceuticals (“SP”), Human Genetic Therapies (“HGT”) and RM.

On May 2, 2013 the Company announced that there would be a reorganization of the Company's business to integrate these business units into a simplified “One Shire” organization in order to drive future growth and innovation. Consequently the SP, HGT and RM segmentsno longer exist.

Shire now comprises a single operating and reportable segment, consistent with the “One Shire” approach that underpins the business simplification. This segment is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. This segment is supported by several key functions: a global research and development organization and a global supply chain organization, managed through the newly established pipeline group and technical operations group respectively, are utilized and responsible for the development and delivery of products to the market. Products are distributed and sold through the newly established in-line marketed products group which consists of five commercial units focused exclusively on commercial delivery to drive optimum performance of currently marketed products. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be an operating segment.

The reorganization to a single operating and reportable segment is consistent with the financial information regularly reviewed by the Executive Committee (which is Shire's chief operating decision maker) for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods.

In the periods set out below, revenues by major product were as follows:

	3 months to,	3 months to,	9 months to,	9 months to,
	September 30,	September 30,	September 30,	September 30,
	2013	2012	2013	2012
	$’M	$’M	$’M	$’M
	___________	___________	___________	___________
VYVANSE	299.2	247.1	897.9	773.3
LIALDA/MEZAVANT	141.9	104.4	379.9	288.5
ELAPRASE	129.1	110.5	392.6	358.3
REPLAGAL	108.5	121.7	336.6	379.3
VPRIV	87.8	74.9	251.9	229.3
ADDERALL XR	81.4	102.2	293.5	347.5
INTUNIV	80.8	69.0	248.9	206.6
PENTASA	70.6	67.0	215.2	196.7
FIRAZYR	62.6	30.3	153.8	81.7
FOSRENOL	51.9	38.1	136.3	126.8
XAGRID	24.2	22.0	74.1	70.7
DERMAGRAFT	23.9	33.7	64.7	134.9
Other product sales	33.0	33.6	96.4	115.5
	____________	____________	____________	____________
Total product sales	1,194.9	1,054.5	3,541.8	3,309.1
	____________	____________	____________	____________

Further segment disclosures related to geographic area and major customers will be included in the 2013 Annual Report on Form 10-K.